News
Complete Response Letter for Ryanodex to treat exertional heat stroke.- Eagle Pharma
Eagle Pharma has received a further Complete Response Letter for its New Drug Application (“NDA”) for Ryanodex for the treatment of exertional heat stroke (“EHS”).
Eagle has decided that it will no longer pursue this indication.
Condition: Exertional Heat Stroke
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.